Skip to main content

Table 1 SMNa Risk

From: Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Treatment Arm

Dexrazoxane

Doxorubicin

Ifosfamide

Etoposide

AOST0121 HER2+

3.75 g/m2

375 mg/m2

51 g/m2

1.5 g/m2

AOST0121 HER2-

3.75 g/m2

375 mg/m2

51 g/m2

1.5 g/m2

P9754 Pilot 1 Good Response

4.5 g/m2

450 mg/m2

  

P9754 Pilot 1 Standard Response

6 g/m2

600 mg/m2

  

P9754 Pilot 2 Good Response

4.5 g/m2

450 mg/m2

27 g/m2

 

P9754 Pilot 2 Standard Response

6 g/m2

600 mg/m2

45 g/m2

 

P9754 Pilot 3 Good Response

4.5 g/m2

450 mg/m2

27 g/m2

 

P9754 Pilot 3 Standard Response

4.5 g/m2

450 mg/m2

60 g/m2

1.5 g/m2

  1. aSMN second malignant neoplasms